On March 13, 2026, Xenetic Biosciences, Inc. announced its financial results for the year ended December 31, 2025, reporting a net loss of approximately $2.7 million. The company ended the year with $7.9 million in cash, reflecting a strategic focus on advancing its DNase-based technology.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.